ANDI
MCID: DBT088
MIFTS: 56

Diabetes Insipidus, Nephrogenic (ANDI) malady

Categories: Genetic diseases, Rare diseases, Nephrological diseases

Aliases & Classifications for Diabetes Insipidus, Nephrogenic

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 23GeneReviews, 24GeneTests, 25Genetics Home Reference, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Diabetes Insipidus, Nephrogenic:

Name: Diabetes Insipidus, Nephrogenic 52 25 12 39
Nephrogenic Diabetes Insipidus 11 23 48 24 25 54 13 68
Vasopressin-Resistant Diabetes Insipidus 11 48 25
Diabetes Insipidus Nephrogenic 48 27 50
Diabetes Insipidus, Nephrogenic, Autosomal 70 27
Congenital Nephrogenic Diabetes Insipidus 25 68
Diabetes Insipidus, Nephrogenic, X-Linked 70 27
Diabetes Insipidus Nephrogenic Type 1 48 70
Adh-Resistant Diabetes Insipidus 25 68
Ndi 24 25
 
Nephrogenic Diabetes Insipidus, Autosomal 24
Nephrogenic Diabetes Insipidus, X-Linked 24
Diabetes Insipidus Nephrogenic X-Linked 48
Diabetes Insipidus Nephrogenic Type 2 70
Adh Resistant Diabetes Insipidus 48
Diabetes Insipidus Renalis 25
Ndi, Autosomal 24
Ndi, X-Linked 24
Andi 70
Xndi 70

Characteristics:

Orphanet epidemiological data:

54
nephrogenic diabetes insipidus:
Inheritance: Autosomal dominant,Autosomal recessive,X-linked recessive; Prevalence: 1-9/1000000 (Europe),1-9/1000000; Age of onset: Infancy,Neonatal


Classifications:

Orphanet: 54 
Rare renal diseases


External Ids:

Disease Ontology11 DOID:12387
ICD1030 N25.1
ICD9CM32 588.1
MeSH39 D018500
NCIt45 C84919
Orphanet54 ORPHA223
MESH via Orphanet40 D018500
UMLS via Orphanet69 C0162283
ICD10 via Orphanet31 N25.1

Summaries for Diabetes Insipidus, Nephrogenic

About this section
NIH Rare Diseases:48 Nephrogenic diabetes insipidus is a disorder in which a defect in the small tubes (tubules) in the kidneys causes a person to produce a large amount of urine. nephrogenic diabetes insipidus occurs when the kidney tubules, which allow water to be removed from the body or reabsorbed, do not respond to a chemical in the body called antidiuretic hormone (adh) or vasopressin. adh normally tells the kidneys to make the urine more concentrated. as a result of the defect, the kidneys release an excessive amount of water into the urine, producing a large quantity of very dilute urine. the most common symptoms are frequent urination (polyuria), especially during nighttime (nocturia), and drinking too much liquids (polydipsia). it can be either acquired or hereditary. the acquired form is brought on by certain drugs and chronic diseases and can occur at any time during life. about 90% of all cases of hereditary nephrogenic diabetes insipidus result from mutations in the avpr2 gene, and about  10% of cases are caused by mutations in the aqp2 gene. treatment consists of plenty of water intake; medication, such as thiazide diuretics and nsaids; and a low-salt, low-protein diet. last updated: 12/23/2016

MalaCards based summary: Diabetes Insipidus, Nephrogenic, also known as nephrogenic diabetes insipidus, is related to diabetes insipidus, nephrogenic, with mental retardation and intracerebral calcification and diabetes insipidus, neurohypophyseal, and has symptoms including Array, Array and Array. An important gene associated with Diabetes Insipidus, Nephrogenic is AVPR2 (Arginine Vasopressin Receptor 2), and among its related pathways are Diuretics Pathway, Pharmacodynamics and Vasopressin-regulated water reabsorption. Affiliated tissues include kidney, and related mouse phenotypes are growth/size/body region and behavior/neurological.

Disease Ontology:11 An impaired renal function disease characterized by a complete or partial resistance of the kidneys to vasopressin (ADH).

Genetics Home Reference:25 Nephrogenic diabetes insipidus is a disorder of water balance. The body normally balances fluid intake with the excretion of fluid in urine. However, people with nephrogenic diabetes insipidus produce too much urine (polyuria), which causes them to be excessively thirsty (polydipsia). Affected individuals can quickly become dehydrated if they do not drink enough water, especially in hot weather or when they are sick.

OMIM:52 Nephrogenic diabetes insipidus is caused by the inability of the renal collecting ducts to absorb water in response to... (125800) more...

UniProtKB/Swiss-Prot:70 Diabetes insipidus, nephrogenic, autosomal: A disorder caused by the inability of the renal collecting ducts to absorb water in response to arginine vasopressin. Characterized by excessive water drinking (polydipsia), excessive urine excretion (polyuria), persistent hypotonic urine, and hypokalemia. Inheritance can be autosomal dominant or recessive. Diabetes insipidus, nephrogenic, X-linked: A disorder caused by the inability of the renal collecting ducts to absorb water in response to arginine vasopressin. Characterized by excessive water drinking (polydipsia), excessive urine excretion (polyuria), persistent hypotonic urine, and hypokalemia.

Wikipedia:71 Nephrogenic diabetes insipidus (also known as renal diabetes insipidus) is a form of diabetes insipidus... more...

Description from OMIM:52 304800

GeneReviews for NBK1177

Related Diseases for Diabetes Insipidus, Nephrogenic

About this section

Diseases related to Diabetes Insipidus, Nephrogenic via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 27)
idRelated DiseaseScoreTop Affiliating Genes
1diabetes insipidus, nephrogenic, with mental retardation and intracerebral calcification12.2
2diabetes insipidus, neurohypophyseal10.8
3diabetes insipidus10.5
4chromosome xq28 duplication syndrome10.3AVP, AVPR2
5diverticulitis of colon10.2AVP, AVPR2
6syringomelia hyperkeratosis10.2AQP2, AVP, AVPR2
7major affective disorder 210.2ARHGAP4, L1CAM
8cataract 29, coralliform10.1AQP2, AVP
9kidney leiomyosarcoma10.1AQP1, AQP3
10mixed lacrimal gland cancer10.1AQP1, AVP
11laryngitis10.1AQP1, AQP2, AVP
12iida kannari syndrome10.1AQP1, AQP2
13cascade stomach10.1AQP1, AQP3
14childhood brainstem astrocytoma10.1AQP1, AQP4
15superior vena cava syndrome10.1AQP1, AQP4
16impetigo10.1AQP1, AQP3, SLC12A1
17calcinosis10.0AQP2, ATP6V0A4, AVP
18intestinal disaccharidase deficiency10.0AQP2, AVP
19ehlers-danlos syndrome, kyphoscoliotic form10.0AQP1, AQP4, MIP
20kindler syndrome10.0AQP2, AVP, AVPR2, LNPEP
21histiocytoid hemangioma10.0AQP1, AQP4, MIP
22ovarian disease10.0AQP1, AQP4
23glossopharyngeal nerve neoplasm9.9AQP2, AQP4, AVP, AVPR2
24urethral gland abscess9.6AQP1, AQP2, AQP3, AQP4, AQP7, MIP
25fatty liver disease9.5AQP2, AQP3, ARHGAP4, AVP, AVPR2, CLCNKA
26prediabetes syndrome9.3AQP1, AQP2, AQP3, ARHGAP4, ATP6V0A4, AVP
27basal cell carcinoma 48.3AQP1, AQP2, AQP3, AQP4, AQP7, ARHGAP4

Comorbidity relations with Diabetes Insipidus, Nephrogenic via Phenotypic Disease Network (PDN):


Bipolar DisorderAcute Cystitis
Diabetes Insipidus

Graphical network of the top 20 diseases related to Diabetes Insipidus, Nephrogenic:



Diseases related to diabetes insipidus, nephrogenic

Symptoms & Phenotypes for Diabetes Insipidus, Nephrogenic

About this section

Symptoms by clinical synopsis from OMIM:

125800

Clinical features from OMIM:

125800,304800

Human phenotypes related to Diabetes Insipidus, Nephrogenic:

 54 64 (show all 30)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 short stature64 54 Occasional (29-5%) HP:0004322
2 hypovolemia64 54 Occasional (29-5%) HP:0011106
3 feeding difficulties64 54 Occasional (29-5%) HP:0011968
4 global developmental delay64 54 Very rare (<4-1%) HP:0001263
5 polyhydramnios64 54 Very rare (<4-1%) HP:0001561
6 enuresis nocturna64 54 Very rare (<4-1%) HP:0010677
7 nephrogenic diabetes insipidus64 54 Obligate (100%) HP:0009806
8 hyposthenuria64 54 Very frequent (99-80%) HP:0003158
9 hypernatremia64 54 Very frequent (99-80%) HP:0003228
10 hypernatremic dehydration64 54 Very frequent (99-80%) HP:0004906
11 failure to thrive64 54 Frequent (79-30%) HP:0001508
12 fever64 54 Frequent (79-30%) HP:0001945
13 polydipsia64 54 Frequent (79-30%) HP:0001959
14 nausea and vomiting64 54 Frequent (79-30%) HP:0002017
15 constipation64 54 Frequent (79-30%) HP:0002019
16 anorexia64 54 Frequent (79-30%) HP:0002039
17 functional abnormality of the bladder54 Occasional (29-5%)
18 hydroureter64 54 Occasional (29-5%) HP:0000072
19 renal insufficiency64 54 Occasional (29-5%) HP:0000083
20 seizures64 54 Occasional (29-5%) HP:0001250
21 growth delay54 Occasional (29-5%)
22 megacystis64 HP:0000021
23 polyuria64 HP:0000103
24 irritability64 HP:0000737
25 intellectual disability64 HP:0001249
26 unexplained fevers64 HP:0001955
27 hypertonic dehydration64 HP:0001986
28 vomiting64 HP:0002013
29 feeding difficulties in infancy64 HP:0008872
30 diabetes insipidus64 HP:0000873

MGI Mouse Phenotypes related to Diabetes Insipidus, Nephrogenic according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053787.7AQP1, AQP2, AQP3, AQP4, AQP7, ATP6V0A4
2MP:00053867.5AQP1, AQP2, AQP3, AQP4, ATP6V0A4, AVP
3MP:00053767.2AQP1, AQP2, AQP3, AQP4, AQP7, ATP6V0A4
4MP:00053676.9AQP1, AQP2, AQP3, AQP4, AQP7, ATP6V0A4

Drugs & Therapeutics for Diabetes Insipidus, Nephrogenic

About this section

Drugs for Diabetes Insipidus, Nephrogenic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 82)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Conivaptanapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 121210101-16-9151171
Synonyms:
210101-16-9
4'-((4,5-dihydro-2-Methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide
4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide
AC1L45SX
CHEBI:681850
CHEMBL1755
CID151171
Conivaptan
Conivaptan (INN)
Conivaptan [INN]
D07748
DB00872
 
I14-8805
L001073
L001531
LS-187117
MolPort-005-940-873
N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide
N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}biphenyl-2-carboxamide
PDSP1_001735
PDSP2_001718
UNII-0NJ98Y462X
YM 087
YM-087
YM087
ZINC12503187
2
Furosemideapproved, vet_approvedPhase 4, Phase 3, Phase 2, Phase 119354-31-93440
Synonyms:
2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid
4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid
4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid
4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
41733-55-5 (mono-hydrochloride salt)
5-18-09-00555 (Beilstein Handbook Reference)
54-31-9
AB00052001
AC-11067
AC1L1FXW
AC1Q557O
AKOS000266625
ARONIS24304
Acetic acid potassium salt
Aisemide
Aldalix
Aldic
Aluzine
Anfuramaide
Apo-Frusemide
Apo-Furosemide
Aquarid
Aquasin
Arasemide
BIDD:GT0139
BPBio1_000443
BRD-K78010432-001-05-8
BRN 0840915
BSPBio_000401
BSPBio_002054
Beronald
Bio-0044
Bioretic
Bristab
Bristurin
C12H11ClN2O5S
CAS-54-31-9
CCRIS 1951
CHEBI:47426
CHEMBL35
CID3440
CPD000058202
Cetasix
Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure
Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]
D00331
D005665
DB00695
DB07799
Depix
Desal
Desdemin
Di-Ademil
Dihydroflumethiazide
Dirine
Disal
Discoid
Disemide
Diucardin
Diumide-K
Diural
Diurapid
Diuretic Salt
Diuretic salt
Diurin
Diurolasa
Diusemide
Diusil
Diuzol
DivK1c_000575
Dranex
Dryptal
Durafurid
EINECS 200-203-6
Edemid
Edenol
Eliur
Elodrine
Endural
Errolon
Eutensin
F0182
F4381_SIGMA
FUN
FUROSEMIDE USP
Farsix
Finuret
Fluidrol
Fluss
Franyl
Frumex
Frumide
Frumil
Frusedan
Frusema
Frusemid
Frusemide
Frusemin
Frusenex
Frusetic
Frusid
Fu sid
Fulsix
Fuluvamide
Fuluvamine
Furanthril
Furanthryl
Furantral
Furantril
Furanturil
Furesis
Furetic
Furex
Furfan
Furix
Furmid
Furo-Basan
Furo-Puren
Furo-puren
Furobeta
Furocot
Furodiurol
Furodrix
Furomen
Furomex
Furomide M.D
Furomide M.D.
Furorese
Furosan
Furose
Furosedon
Furosemid
Furosemida
Furosemida [INN-Spanish]
Furosemide
Furosemide "mita"
Furosemide (JP15/USP/INN)
Furosemide Monohydrochloride
Furosemide Monosodium Salt
Furosemide [USAN:INN:JAN]
Furosemidu
Furosemidu [Polish]
Furosemidum
Furosemidum [INN-Latin]
Furosemix
Furoside
Furosifar
Furosix
Furoter
Furovite
Fursemid
Fursemida
Fursemide
Fursol
Fusid
Fusidic acid
 
Golan
HMS1569E03
HMS1920B03
HMS2090K06
HMS2091H05
HMS501M17
HSDB 3086
Hissuflux
Hoe-058A
Hydol
Hydrenox
Hydrex
Hydro
Hydro-Rapid
Hydro-rapid
Hydroled
I04-0179
IDI1_000575
Impugan
Jenafusid
KBio1_000575
KBio2_001580
KBio2_004148
KBio2_006716
KBio3_001274
KBioGR_001259
KBioSS_001580
Katlex
Kofuzon
Kolkin
Kutrix
LB 502
LB-502
LS-204
Lasemid
Lasex
Lasiletten
Lasilix
Lasix
Lasix (TN)
Lasix (tn)
Lasix Retard
Lasix Special
Lasix, Frusemide, Furosemide
Laxur
Lazix
Leodrine
Less Diur
Liside
Logirene
Lowpston
Lowpstron
Luscek
MLS001066374
MLS001306403
Macasirool
Marsemide
Metflorylthiazidine
Methforylthiazidine
Mirfat
Mita
Moilarorin
MolPort-001-641-065
Myrosemide
NCGC00016241-01
NCGC00090893-01
NCGC00090893-02
NCGC00090893-03
NCGC00090893-05
NCGC00090893-06
NCI-C55936
NINDS_000575
NSC 269420
NSC269420
Nadis
Nelsix
Neo-Renal
Neo-renal
Nephron
Nicorol
Novosemide
Octan Draselny
Octan draselny
Odemase
Odemex
Oedemex
Olmagran
Oprea1_667724
Osyrol
Polysquall A
Prefemin
Prestwick0_000341
Prestwick1_000341
Prestwick2_000341
Prestwick3_000341
Prestwick_752
Profemin
Promedes
Promide
Protargen
Puresis
Radisemide
Radonna
Radouna
Retep
Rodiuran
Rontyl
Rosemide
Rosis
Rusyde
S1603_Selleck
SAM002264614
SMP1_000129
SMR000058202
SPBio_001129
SPBio_002322
SPECTRUM1500310
STK177334
Sal Diureticum
Sal diureticum
Salinex
Salix
Salix (brand of furosemide)
Salurex
Salurid
Saluron
Seguril
Selectofur
Sigasalur
Sisuril
Spectrum2_001005
Spectrum3_000437
Spectrum4_000560
Spectrum5_000744
Spectrum_001100
Spirofur
Synephron
TL8003563
Transit
Trofurit
UNII-7LXU5N7ZO5
UPCMLD-DP022
UPCMLD-DP022:001
Uremide
Uresix
Urex
Urex-M
Urian
Uridon
Uritol
Urosemide
Vergonil
Vesix
WLN: T5OJ B1MR CG FVQ DSZW
Yidoli
Zafimida
fulvamide
furosemide
furosemide ''mita''
less Diur
3
TolvaptanapprovedPhase 4, Phase 3, Phase 2, Phase 190150683-30-0216237
Synonyms:
( -)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-o-tolu-m-toluidide
150683-30-0
7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine
AC1L50C9
C116664
CHEBI:327437
CHEMBL344159
CID216237
 
L001628
N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide
OPC 41061
OPC-41061
PDSP1_001738
PDSP2_001721
Samsca
Tolvaptan
UNII-21G72T1950
benzazepine derivative, 32
4
Chlorothiazideapproved, vet_approvedPhase 4758-94-62720
Synonyms:
2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide
58-94-6
6-Chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide
6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
6-Chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
6-chloro-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
6-chloro-7-Sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
AC-18732
AC1L1EBB
Aldoclor
Alurene
BIDD:GT0635
BPBio1_000070
BRD-K88682005-001-05-9
BSPBio_000062
BSPBio_002003
C 4911
C07461
C2259
C4911_SIGMA
C7H6ClN3O4S2
CAS-58-94-6
CCRIS 5999
CHEBI:3640
CHEMBL842
CID2720
CPD000058429
Chloriazid
Chlorosal
Chlorothiazid
Chlorothiazide
Chlorothiazide (JAN/USP/INN)
Chlorothiazide [USAN:INN:BAN]
Chlorothiazidum
Chlorothiazidum [INN-Latin]
Chlorthiazid
Chlorthiazide
Chlorthiazidum
Chlortiazid
Chlorurit
Chlotride
Chlrosal
Clorotiazida
Clorotiazida [INN-Spanish]
Clorotiazide
Clorotiazide [DCIT]
Clotride
D002740
D00519
DB00880
Diupres
Diuresal
Diuril
Diuril (TN)
Diuril Boluses
Diuril Boluses, Veterinary
Diuril, Chlotride, Chlorothiazide
Diurilix
Diurite
Diutrid
DivK1c_000675
EINECS 200-404-9
EU-0100254
Flumen
HMS1568D04
 
HMS1920K15
HMS2091C18
HMS502B17
HSDB 3030
I06-2278
IDI1_000675
KBio1_000675
KBio2_000594
KBio2_003162
KBio2_005730
KBio3_001223
KBioGR_000780
KBioSS_000594
LS-244
Lopac-C-4911
Lopac0_000254
MLS000028398
Mechlozid
Minzil
MolPort-003-666-143
MolPort-003-845-912
NCGC00015242-01
NCGC00015242-02
NCGC00015242-03
NCGC00015242-05
NCGC00015242-09
NCGC00091042-01
NCGC00091042-02
NCGC00091042-03
NCGC00091042-04
NCGC00091042-05
NINDS_000675
NSC 25693
NSC25693
Neo-Dema
Prestwick0_000251
Prestwick1_000251
Prestwick2_000251
Prestwick3_000251
Prestwick_56
S1641_Selleck
SAM002554891
SMR000058429
SPBio_000288
SPBio_002281
SPECTRUM1500180
Salisan
Salunil
Saluretil
Saluric
Sk-chlorothiazide
Spectrum2_000154
Spectrum3_000342
Spectrum4_000280
Spectrum5_001446
Spectrum_000134
Thiazide
UNII-77W477J15H
Urinex
Uroflux
WLN: T66 BSWM ENJ HG ISZW
Warduzide
Yadalan
chlorothiazide
chlorotiazida
component of Aldoclor
5
MetolazoneapprovedPhase 4, Phase 11417560-51-94170
Synonyms:
17560-51-9
2-Methyl-3-O-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone
2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone
5-25-09-00212 (Beilstein Handbook Reference)
7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide
7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-O-tolyl-6-quinazolinesulfonamide
7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide
7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide
AB00052055
AC1L1HKJ
BPBio1_000138
BRD-A61793559-001-05-7
BRN 0965506
BSPBio_000124
BSPBio_002422
CHEMBL878
CID4170
D00431
DB00524
Diulo
DivK1c_000275
EINECS 241-539-3
HMS1568G06
HMS1922L16
HMS2093P14
HMS500N17
HSDB 3367
IDI1_000275
KBio1_000275
KBio2_000936
KBio2_003504
KBio2_006072
KBioGR_000897
KBioSS_000936
LS-140226
M1195_SIGMA
MLS002153316
MLS002154200
Metalazone
Metalozone
Metenix
 
Metolazon
Metolazona
Metolazona [INN-Spanish]
Metolazone (JAN/USP/INN)
Metolazone [USAN:BAN:INN:JAN]
Metolazonum
Metolazonum [INN-Latin]
Microx
MolPort-003-666-780
Mykrox
Mykrox, Zaroxolyn, Diulo, Metolazone
Métolazone
NCGC00093985-01
NCGC00093985-02
NCGC00093985-03
NCGC00093985-04
NCGC00093985-05
NCGC00093985-06
NCGC00093985-08
NINDS_000275
Oldren
Prestwick0_000112
Prestwick1_000112
Prestwick2_000112
Prestwick3_000112
Prestwick_333
S1610_Selleck
SMR001230730
SPBio_001842
SPBio_002063
SPECTRUM2300325
SR 720-22
SR-720-22
Spectrum2_001741
Spectrum4_000229
Spectrum5_001237
Spectrum_000456
UNII-TZ7V40X7VX
Xuret
Zaroxolyn
Zaroxolyn (TN)
metolazone
6diureticsPhase 4, Phase 3, Phase 2, Phase 11418
7Sodium Potassium Chloride Symporter InhibitorsPhase 4, Phase 3, Phase 2, Phase 1181
8VasopressinsPhase 4, Phase 3, Phase 2, Phase 1294
9HormonesPhase 4, Phase 3, Phase 2, Phase 114415
10Arginine VasopressinPhase 4, Phase 3, Phase 2, Phase 1299
11Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 14067
12Natriuretic AgentsPhase 4, Phase 3, Phase 2, Phase 11697
13Vasoconstrictor AgentsPhase 4, Phase 3, Phase 2, Phase 12122
14Sodium Chloride Symporter InhibitorsPhase 4, Phase 1452
15TorsemidePhase 422
16Antihypertensive AgentsPhase 4, Phase 14207
17HemostaticsPhase 4, Phase 3, Phase 2, Phase 11443
18CoagulantsPhase 4, Phase 3, Phase 2, Phase 11500
19Pharmaceutical SolutionsPhase 48192
20arginineNutraceuticalPhase 4, Phase 3, Phase 2, Phase 1425
21
MidodrineapprovedPhase 2, Phase 347133163-28-7, 42794-76-34195
Synonyms:
( -)-Midodrin hydrochloride
( -)-Midodrine hydrochloride
()-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol
(+-)-1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride
(+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride
(+-)-2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide
(+-)-Midodrine hydrochloride
(+/-)-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol
(RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid
1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol
1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride
2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid
2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide
2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide
2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride
2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hyyroxyethyl)acetamide monohydrochloride
2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide
2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide hydrochloride
3092-17-9
3092-17-9 (mono-hydrochloride)
42794-76-3
42794-76-3 (Parent)
43218-56-0
97476-58-9
A 4020 Linz
A-4020 Linz
AB00053715
AC1L1HMJ
AC1L2BU9
Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-, monohydrochloride
Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, hydrochloride
Alphamine
Amatine
BPBio1_000157
BRD-A79981887-003-05-7
BSPBio_000141
BSPBio_003150
C07890
C12H18N2O4
C12H18N2O4.HCl
CHEBI:31847
CHEBI:6933
CHEMBL1200461
CID18340
CID4195
CPD000058833
D01307
D08220
DB00211
DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid
DivK1c_000955
EINECS 255-945-3
EINECS 256-148-3
Gutron
HMS1568H03
HMS1922O03
Hipertan
I06-0865
IDI1_000955
KBio1_000955
KBio2_002121
KBio2_004689
KBio2_007257
 
KBio3_002650
KBioGR_000763
KBioSS_002121
LS-174957
LS-8042
LS-8052
M8277_FLUKA
M8277_SIGMA
MIDODRINE HYDROCHLORIDE
MLS001332567
MLS001332568
MLS002154233
Metligene
Midamine
Midodrin
Midodrina
Midodrina [INN-Spanish]
Midodrine (INN)
Midodrine HCL
Midodrine Monohydrochloride
Midodrine [BAN:INN]
Midodrine [INN:BAN]
Midodrine hydrochloride
Midodrine hydrochloride (JAN/USAN)
Midodrine hydrochloride [USAN:JAN]
Midodrine hydrochloride [USAN]
Midodrinum
Midodrinum [INN-Latin]
MolPort-003-666-473
MolPort-003-849-221
N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide
N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide
NCGC00095311-01
NCGC00178238-01
NCGC00178238-02
NINDS_000955
Prestwick0_000191
Prestwick1_000191
Prestwick2_000191
Prestwick3_000191
Prestwick_625
Pro-Amatine
Pro-Amatine (TN)
ProAmatine
SAM002564219
SBB066174
SMR000058833
SPBio_001390
SPBio_002062
SPECTRUM1503257
ST-1085
Spectrum2_001545
Spectrum3_001585
Spectrum4_000192
Spectrum5_000962
Spectrum_001641
St 1085
St. Peter 224
TL8002369
TS 701
UNII-59JV96YTXV
UNII-6YE7PBM15H
[+/-]-1-[2,5-Dimethoxyphenyl]-2-glycinamidoethanol
midodrine
22
SpironolactoneapprovedPhase 2, Phase 32321952-01-7, 52-01-75833
Synonyms:
4-18-00-01601 (Beilstein Handbook Reference)
4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate
496916-40-6
52-01-7
7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone
7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
AB00513806
AC-4214
AC1L1L8Q
Abbolactone
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone (TN)
Aldactone A
Alderon
Aldopur
Almatol
Alphapharm Brand of Spironolactone
Alpharma Brand of Spironolactone
Alter Brand of Spironolactone
Altex
Aquareduct
Ashbourne Brand of Spironolactone
Azupharma Brand of Spironolactone
BIDD:PXR0071
BPBio1_000194
BRD-K90027355-001-03-4
BRN 0057767
BSPBio_000176
C07310
C24H32O4S
CHEBI:428201
CHEBI:45692
CHEBI:9241
CHEMBL1393
CID5833
CPD000471892
Cardel Brand of Spironolactone
D00443
D013148
DB00421
Deverol
Dexo Brand of Spironolactone
Diatensec
Dira
Duraspiron
EINECS 200-133-6
Espironolactona
Espironolactona Alter
Espironolactona Mundogen
Espironolactona [INN-Spanish]
Euteberol
Flumach
Frumikal
Generosan Brand of Spironolactone
HMS1568I18
HMS2090N21
HSDB 3184
Hormosan Brand of Spironolactone
I06-1970
Jenapharm Brand of Spironolactone
Jenaspiron
LS-118614
LT00772287
Lacalmin
Lacdene
Laractone
MLS001074672
MLS001333253
MLS001333254
MLS002153245
MLS002207058
Mayoly-Spindler Brand of Spironolactone
Melarcon
Merck dura Brand of Spironolactone
Mundogen Brand of Spironolactone
NCGC00164397-01
 
NCGC00164397-02
NSC 150399
NSC150399
Nefurofan
Novo Spiroton
Novo-Spiroton
NovoSpiroton
Novopharm Brand of Spironolactone
Osyrol
Pfizer Brand of Spironolactone
Pharmafrid Brand of Spironolactone
Practon
Prestwick0_000128
Prestwick1_000128
Prestwick2_000128
Prestwick3_000128
Roche Brand of Spironolactone
S0260
S3378_SIGMA
SAM002264648
SC 9420
SC-9420
SC9420
SMR000471892
SNL
SPBio_002115
Sagisal
Searle Brand of Spironolactone
Sincomen
Spiractin
Spiresis
Spiretic
Spiridon
Spiro L.U.T.
Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan)
Spiro-Tablinen
Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]
Spirobeta
Spiroctan
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
Spirono Isis
Spirono-Isis
Spironocompren
Spironolactone
Spironolactone (JP15/USP/INN)
Spironolactone A
Spironolactone [BAN:INN:JAN]
Spironolactone [INN:BAN:JAN]
Spironolactonum
Spironolactonum [INN-Latin]
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
Sprioderm
Supra-puren
Suracton
UNII-27O7W4T232
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
WLN: L E5 B666 FX OV MUTJ A1 E1 KSV1 F-& CT5VOXTJ
Worwag Brand of Spironolactone
Xenalon
ZINC03861599
betapharm Brand of Spironolactone
ct Arzneimittel Brand of Spironolactone
ct-Arzneimittel Brand of Spironolactone
spiro von ct
spironolactone
spironolattone
von ct, spiro
23Neurotransmitter AgentsPhase 2, Phase 318340
24Diuretics, Potassium SparingPhase 2, Phase 31917
25Peripheral Nervous System AgentsPhase 2, Phase 323689
26Autonomic AgentsPhase 2, Phase 310150
27
SatavaptanPhase 3, Phase 211185913-78-47029
Synonyms:
308145-17-7
Aquilda
Benzamide, N-(1,1-dimethylethyl)-4-((cis-5'-ethoxy-4-(2-(4-morpholinyl)ethoxy)-2'-oxospiro(cyclohexane-1,3'-(3H)indol)-1'(2'H)-yl)sulfonyl)-3-methoxy-, phosphate (1:1)
CID9810773
 
SR-121463
SR-121463A
SR-121463B
SR-121463F
Satavaptan
28Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 2, Phase 113168
29Hormone AntagonistsPhase 3, Phase 2, Phase 113180
30Mineralocorticoid Receptor AntagonistsPhase 2, Phase 3346
31Adrenergic alpha-AgonistsPhase 2, Phase 31734
32Adrenergic AgonistsPhase 2, Phase 33027
33MineralocorticoidsPhase 2, Phase 3367
34Adrenergic AgentsPhase 2, Phase 35352
35
Nitric OxideapprovedPhase 261710102-43-9145068
Synonyms:
(.)NO
(NO)(.)
10102-43-9
14332-28-6
295566_ALDRICH
51005-20-0
51005-21-1
53851-19-7
90452-29-2
AC1L1ADQ
AC1L3QHF
AC1Q6QZ0
AR-1K7463
Bioxyde d'azote
Bioxyde d'azote [French]
C00533
CCRIS 4319
CHEMBL1200689
CHEMBL1234765
CID145068
CID945
D00074
D009569
DB00435
EDRF
EINECS 233-271-0
Endogenous Nitrate Vasodilator
Endothelium-Derived Nitric Oxide
HNO
HSDB 1246
INOmax
INOmax (TN)
LS-192158
LS-7547
MolPort-003-929-452
Mononitrogen monoxide
Monoxide, Mononitrogen
Monoxide, Nitrogen
Monoxido de nitrogeno
Monoxyde d'azote
NITRIC-OXIDE
NO
NO(.)
Nitrate Vasodilator, Endogenous
Nitric Oxide, Endothelium Derived
 
Nitric Oxide, Endothelium-Derived
Nitric oxide
Nitric oxide (JAN)
Nitric oxide 10% by volume or more
Nitric oxide trimer
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, compressed [UN1660] [Poison gas]
Nitrogen monoxide
Nitrogen oxide
Nitrogen oxide (NO)
Nitrogen protoxide
Nitrosyl
Nitrosyl hydride
Nitrosyl hydride ((NO)H)
Nitrosyl radical
Nitroxide radical
Nitroxyl
OHM 11771
Oxide, Nitric
Oxido de nitrogeno(ii)
Oxido nitrico
Oxyde azotique
Oxyde nitrique
Oxyde nitrique [French]
RCRA waste no. P076
Stickmonoxyd
Stickmonoxyd [German]
Stickstoff(II)-oxid
Stickstoff(ii)-oxid
Stickstoffmonoxid
UN 1660
UN1660
UNII-31C4KY9ESH
Vasodilator, Endogenous Nitrate
[NO]
endothelium-derived relaxing factor
monoxido de nitrogeno
monoxyde d'azote
nitric oxide
nitrogen monooxide
nitrogen monoxide
nitrosyl
oxido de nitrogeno(II)
oxido nitrico
oxidonitrogen(.)
oxoazanyl
oxyde azotique
36
Phentermineapproved, illicitPhase 241122-09-84771
Synonyms:
(alpha,alpha)-Dimethylphenethylamine
1,1-Dimethyl-2-phenylethylamine
1-(2-Methylphenyl)-2-propylamin
1-(2-Tolyl)-2-propylamine
1197-21-3 (hydrochloride)
122-09-8
12674-13-4
2-Amino-2-methyl-1-phenylpropane
2-Methyl-1-phenyl-2-propanamine
2-Phenyl-tert-butylamine
2-methyl-1-phenylpropan-2-amine
35373-71-8
9008-94-0
AC1L1IX2
AKOS004123261
Adipex-P
AmbkkkkK744
BRN 0970319
C07438
CHEBI:8080
CHEMBL1574
CID4771
D05458
DB00191
DEA No. 1640
Duromine
EINECS 204-522-1
Fastin
Fentermina
Fentermina [INN-Spanish]
HMS2093B16
HSDB 3158
InChI=1/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H
Inoamin
Ionamin
Ionamine
LS-103327
Linyl
Lipopill
 
Lonamin
Mirapront
MolPort-002-043-208
Normephentermine
Obenix
Obermine
Oby-Trim
Omnibex
Ona Mast
Ortetamin
Ortetamina
Ortetamine [INN]
Ortetaminum
Phentercot
Phentermine (USAN/INN)
Phentermine HCl
Phentermine Resin 30
Phentermine [USAN:INN:BAN]
Phentermine resin complex
Phenterminum
Phenterminum [INN-Latin]
Phentride
Phentrol
Phentrol 2
Phentrol 3
Phentrol 4
Phenyl-tert-butylamine
Phenyl-tertiary-butylamine
Pro-Fast
RCRA waste no. P046
RCRA waste number P046
UNII-C045TQL4WP
UNII-VF4N11KKKR
Wilpo
Zantryl
alpha,alpha-Dimethyl-beta-phenylethylamine
alpha,alpha-Dimethylbenzeneethanamine
alpha,alpha-Dimethylphenethylamine
alpha-Benzylisopropylamine
alpha.,.alpha.-dimethyl-Benzeneethanamine
phentermine
37
Mannitolapproved, investigationalPhase 228069-65-8453, 6251
Synonyms:
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
AR-1J3861
Ambap69-65-8
BRN 1721898
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-Mannitol
D-Mannitol (JP15)
D-mannite
D-mannitol
D00062
D008353
DL-Mannitol
Diosmol
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Fraxinine
HSDB 714
Hexahydroxyhexane
Hexanhexol
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
M9546_SIAL
M9647_SIAL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
 
MANNITOL 25%
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
MLS001335977
MLS001335978
MTL
Manicol
Manitol
Maniton S
Maniton-S
Manna Sugar
Manna sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol 10%
Mannitol 10% In Plastic Container
Mannitol 15%
Mannitol 15% In Plastic Container
Mannitol 20%
Mannitol 20% In Plastic Container
Mannitol 5%
Mannitol 5% In Plastic Container
Mannitol [USAN]
Mannitolum
Mannogem 2080
Marine Crystal
Marine crystal
MolPort-003-927-039
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
Osmitrol 15% In Water
Osmitrol 20% In Water
Osmitrol 5% In Water
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM No. 35
SMR000857324
SORBITOL-MANNITOL IN PLASTIC CONTAINER
Sorbitol-Mannitol
TL806434
UNII-3OWL53L36A
ZINC02041302
bmse000099
cpd without stereochemical designation
e 421
e-421
e421
manita
mannitol
38Respiratory System AgentsPhase 24997
39Vasodilator AgentsPhase 23543
40Calcium, DietaryPhase 2, Phase 15713
41SRX246Phase 1, Phase 27
42Protective AgentsPhase 27443
43AntioxidantsPhase 23050
44omega-N-MethylargininePhase 260
45Anti-Asthmatic AgentsPhase 23488
46Endothelium-Dependent Relaxing FactorsPhase 2281
47Bronchodilator AgentsPhase 22965
48Lipid Regulating AgentsPhase 22766
49Lithium carbonatePhase 2240554-13-2
50Hypolipidemic AgentsPhase 22785

Interventional clinical trials:

(show top 50)    (show all 135)
idNameStatusNCT IDPhase
1Tolvaptan for Hyponatremia in Cirrhotic Patients With AscitesUnknown statusNCT01716611Phase 4
2Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With AscitesUnknown statusNCT01552590Phase 4
3Effects of Tolvaptan in Healthy AdultsCompletedNCT01973140Phase 4
4Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure PatientsCompletedNCT01439009Phase 4
5Pilot Study of Using Copeptin to Predict Response to TolvaptanCompletedNCT01346072Phase 4
6Tolvaptan for Ascites in Cirrhotic PatientsCompletedNCT01292304Phase 4
7Tolvaptan in Hyponatremic Cancer PatientsCompletedNCT01199198Phase 4
8A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic HyponatremiaCompletedNCT00435591Phase 4
9Tolvaptan/Ultrafiltration in the Treatment of Acute Heart FailureCompletedNCT01863511Phase 4
10The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves ReplacementCompletedNCT02644616Phase 4
11Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure PatientsCompletedNCT01752543Phase 4
12Regional Tolvaptan RegistryRecruitingNCT02666651Phase 4
13Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart FailureRecruitingNCT02352285Phase 4
14Tolvaptan for Advanced or Refractory Heart FailureRecruitingNCT02959411Phase 4
15Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying RespondersRecruitingNCT02476409Phase 4
16Aquaresis Utility for Hyponatremic Acute Heart Failure StudyRecruitingNCT02183792Phase 4
17Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart FailureEnrolling by invitationNCT02606253Phase 4
18Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and HyponatremiaTerminatedNCT01890694Phase 4
19Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU PatientsTerminatedNCT00727090Phase 4
20The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot StudyWithdrawnNCT01663662Phase 4
21Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous InfusionWithdrawnNCT00806910Phase 4
22Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE)Unknown statusNCT01733134Phase 3
23Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute HyponatremiaUnknown statusNCT01507727Phase 2, Phase 3
24DILIPO (DILutIonal HyPOnatremia)CompletedNCT00274326Phase 3
25International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic HyponatremiaCompletedNCT02449044Phase 3
26Efficacy and Safety of Tolvaptan in Cirrhotic Patients With HyponatremiaCompletedNCT01850940Phase 3
27Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac EdemaCompletedNCT01651156Phase 3
28Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart FailureCompletedNCT01618448Phase 3
29Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume ManagementCompletedNCT01584557Phase 3
30Effect of Tolvaptan on Cognitive Function in CirrhosisCompletedNCT01556646Phase 3
31Phase III Study of Tolvaptan Tablet to Treat Cirrhosis AscitesCompletedNCT01349348Phase 3
32A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]CompletedNCT01280721Phase 3
33Open-Label Tolvaptan Study in Subjects With ADPKDCompletedNCT01214421Phase 3
34A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic EdemaCompletedNCT01114828Phase 3
35A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic EdemaCompletedNCT01050530Phase 3
36A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mgCompletedNCT01048788Phase 3
37A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]CompletedNCT01022424Phase 3
38Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic PatientsCompletedNCT00550459Phase 3
39A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)CompletedNCT00544869Phase 3
40A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)CompletedNCT00525265Phase 3
41Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic HyponatremiaCompletedNCT00492037Phase 3
42Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic HyponatremiaCompletedNCT00478192Phase 3
43A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)CompletedNCT00462670Phase 3
44Tolvaptan Phase 3 Efficacy and Safety Study in ADPKDCompletedNCT00428948Phase 3
45Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic HyponatremiaCompletedNCT00380575Phase 3
46An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic HyponatremiaCompletedNCT00379847Phase 3
47Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)CompletedNCT00358878Phase 3
48"SALT-2 Trial" Study of Ascending Levels of Tolvaptan in HyponatremiaCompletedNCT00201994Phase 3
49“SALT Trial” Study of Ascending Levels of Tolvaptan in HyponatremiaCompletedNCT00072683Phase 3
50EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With TolvaptanCompletedNCT00071331Phase 3

Search NIH Clinical Center for Diabetes Insipidus, Nephrogenic


Cochrane evidence based reviews: diabetes insipidus, nephrogenic

Genetic Tests for Diabetes Insipidus, Nephrogenic

About this section

Genetic tests related to Diabetes Insipidus, Nephrogenic:

id Genetic test Affiliating Genes
1 Nephrogenic Diabetes Insipidus, Autosomal27 24 AQP2
2 Nephrogenic Diabetes Insipidus, X-Linked27 24 AVPR2
3 Nephrogenic Diabetes Insipidus27 24 AVPR2

Anatomical Context for Diabetes Insipidus, Nephrogenic

About this section

MalaCards organs/tissues related to Diabetes Insipidus, Nephrogenic:

36
Kidney

Publications for Diabetes Insipidus, Nephrogenic

About this section

Articles related to Diabetes Insipidus, Nephrogenic:

idTitleAuthorsYear
1
Diabetes insipidus, nephrogenic type, complicating pregnancy: a case report. (5529923)
1970

Variations for Diabetes Insipidus, Nephrogenic

About this section

UniProtKB/Swiss-Prot genetic disease variations for Diabetes Insipidus, Nephrogenic:

70 (show all 110)
id Symbol AA change Variation ID SNP ID
1AQP2p.Gly64ArgVAR_004401rs104894326
2AQP2p.Arg187CysVAR_004402rs104894328
3AQP2p.Ser216ProVAR_004403rs104894329
4AQP2p.Leu22ValVAR_015239rs104894336
5AQP2p.Leu28ProVAR_015240
6AQP2p.Ala47ValVAR_015241
7AQP2p.Asn68SerVAR_015242rs104894331
8AQP2p.Val71MetVAR_015243rs149659001
9AQP2p.Thr125MetVAR_015244rs104894333
10AQP2p.Thr126MetVAR_015245rs104894330
11AQP2p.Ala147ThrVAR_015246rs104894334
12AQP2p.Val168MetVAR_015247rs755694590
13AQP2p.Gly175ArgVAR_015248rs104894335
14AQP2p.Cys181TrpVAR_015249rs104894337
15AQP2p.Pro185AlaVAR_015250rs761713751
16AQP2p.Ala190ThrVAR_015251rs104894341
17AQP2p.Trp202CysVAR_015253
18AQP2p.Glu258LysVAR_015254rs104894332
19AQP2p.Pro262LeuVAR_015255rs104894339
20AQP2p.Gln57ProVAR_015256rs28931580
21AQP2p.Gly100ValVAR_015257rs28929477
22AQP2p.Ala70AspVAR_062585
23AQP2p.Gly100ArgVAR_062586
24AQP2p.Gly180SerVAR_062587
25AQP2p.Arg187HisVAR_062588rs193922495
26AQP2p.Arg254LeuVAR_062589
27AQP2p.Arg254GlnVAR_062590
28AQP2p.Thr108MetVAR_071370
29AVPR2p.Leu44ProVAR_003517
30AVPR2p.His80ArgVAR_003520
31AVPR2p.Val88MetVAR_003521
32AVPR2p.Arg106CysVAR_003522
33AVPR2p.Cys112ArgVAR_003523
34AVPR2p.Arg113TrpVAR_003524rs28935496
35AVPR2p.Ser126PheVAR_003525
36AVPR2p.Tyr128SerVAR_003526
37AVPR2p.Ala132AspVAR_003527rs104894747
38AVPR2p.Arg137HisVAR_003528rs104894756
39AVPR2p.Arg143ProVAR_003529
40AVPR2p.Trp164SerVAR_003531
41AVPR2p.Ser167LeuVAR_003532
42AVPR2p.Ser167ThrVAR_003533
43AVPR2p.Arg181CysVAR_003534rs104894757
44AVPR2p.Gly185CysVAR_003535rs104894748
45AVPR2p.Arg202CysVAR_003536rs782806507
46AVPR2p.Arg203CysVAR_003537rs104894750
47AVPR2p.Tyr205CysVAR_003538rs104894749
48AVPR2p.Tyr280CysVAR_003541rs104894752
49AVPR2p.Ala285ProVAR_003542rs193922122
50AVPR2p.Pro286LeuVAR_003543
51AVPR2p.Pro286ArgVAR_003544
52AVPR2p.Leu292ProVAR_003545
53AVPR2p.Leu309ProVAR_003546
54AVPR2p.Asn317LysVAR_003547
55AVPR2p.Trp323SerVAR_003548
56AVPR2p.Leu43ProVAR_015297
57AVPR2p.Ile46LysVAR_015298rs104894759
58AVPR2p.Leu53ArgVAR_015299
59AVPR2p.Asn55AspVAR_015300
60AVPR2p.Asn55HisVAR_015301
61AVPR2p.Leu59ProVAR_015302rs193922112
62AVPR2p.Leu62ProVAR_015304
63AVPR2p.Leu81PheVAR_015305
64AVPR2p.Leu83ProVAR_015306
65AVPR2p.Leu83GlnVAR_015307
66AVPR2p.Ala84AspVAR_015308
67AVPR2p.Asp85AsnVAR_015309rs104894754
68AVPR2p.Gln92ArgVAR_015310
69AVPR2p.Leu94GlnVAR_015311
70AVPR2p.Pro95LeuVAR_015312
71AVPR2p.Trp99ArgVAR_015313
72AVPR2p.Arg104CysVAR_015314rs104894760
73AVPR2p.Phe105ValVAR_015315rs104894758
74AVPR2p.Gly107GluVAR_015316
75AVPR2p.Cys112TyrVAR_015317
76AVPR2p.Gly122ArgVAR_015318
77AVPR2p.Met123LysVAR_015319
78AVPR2p.Ser127PheVAR_015320
79AVPR2p.Ile130PheVAR_015321rs796052096
80AVPR2p.Leu135ProVAR_015322
81AVPR2p.Ala163ProVAR_015324
82AVPR2p.Pro173SerVAR_015325
83AVPR2p.Gln174LeuVAR_015326
84AVPR2p.Asp191GlyVAR_015327
85AVPR2p.Gly201AspVAR_015328rs104894755
86AVPR2p.Thr204AsnVAR_015329
87AVPR2p.Val206AspVAR_015330
88AVPR2p.Thr207AsnVAR_015331
89AVPR2p.Ile209PheVAR_015332
90AVPR2p.Phe214SerVAR_015333
91AVPR2p.Pro217ThrVAR_015335
92AVPR2p.Leu219ProVAR_015336
93AVPR2p.Leu219ArgVAR_015337
94AVPR2p.Met272LysVAR_015339
95AVPR2p.Val277AlaVAR_015340
96AVPR2p.Leu282ProVAR_015341
97AVPR2p.Pro286SerVAR_015342
98AVPR2p.Phe287LeuVAR_015343
99AVPR2p.Leu289ProVAR_015344
100AVPR2p.Ala294ProVAR_015345
101AVPR2p.Leu309ArgVAR_015346
102AVPR2p.Ser315ArgVAR_015347
103AVPR2p.Cys319ArgVAR_015349
104AVPR2p.Asn321AspVAR_015350
105AVPR2p.Asn321LysVAR_015351rs193922123
106AVPR2p.Asn321TyrVAR_015352
107AVPR2p.Pro322HisVAR_015353
108AVPR2p.Pro322SerVAR_015354
109AVPR2p.Trp323ArgVAR_015355
110AVPR2p.Gly122AspVAR_062591

Clinvar genetic disease variations for Diabetes Insipidus, Nephrogenic:

5 (show all 42)
id Gene Variation Type Significance SNP ID Assembly Location
1AVPR2AVPR2, 1-BP DEL, 733GdeletionPathogenic
2AVPR2NM_ 000054.4(AVPR2): c.395C> A (p.Ala132Asp)SNVPathogenicrs104894747GRCh37Chr X, 153171355: 153171355
3AVPR2NM_ 000054.4(AVPR2): c.553G> T (p.Gly185Cys)SNVPathogenicrs104894748GRCh37Chr X, 153171513: 153171513
4AVPR2NM_ 000054.4(AVPR2): c.614A> G (p.Tyr205Cys)SNVPathogenicrs104894749GRCh37Chr X, 153171574: 153171574
5AVPR2NM_ 000054.4(AVPR2): c.607C> T (p.Arg203Cys)SNVPathogenicrs104894750GRCh37Chr X, 153171567: 153171567
6AVPR2NM_ 000054.4(AVPR2): c.337C> T (p.Arg113Trp)SNVPathogenicrs28935496GRCh37Chr X, 153171297: 153171297
7AVPR2AVPR2, 1-BP INSinsertionPathogenic
8AVPR2NM_ 000054.4(AVPR2): c.213G> A (p.Trp71Ter)SNVPathogenicrs104894751GRCh37Chr X, 153171173: 153171173
9AVPR2NM_ 000054.4(AVPR2): c.839A> G (p.Tyr280Cys)SNVPathogenicrs104894752GRCh37Chr X, 153171799: 153171799
10AVPR2NM_ 000054.4(AVPR2): c.1009C> T (p.Arg337Ter)SNVPathogenicrs104894753GRCh37Chr X, 153172075: 153172075
11AVPR2NM_ 000054.4(AVPR2): c.253G> A (p.Asp85Asn)SNVPathogenicrs104894754GRCh37Chr X, 153171213: 153171213
12AVPR2NM_ 000054.4(AVPR2): c.602G> A (p.Gly201Asp)SNVPathogenicrs104894755GRCh37Chr X, 153171562: 153171562
13AVPR2AVPR2, 1-BP INS, 804GinsertionPathogenic
14AVPR2AVPR2, 1-BP DEL, 102GdeletionPathogenic
15AVPR2NM_ 000054.4(AVPR2): c.410G> A (p.Arg137His)SNVPathogenicrs104894756GRCh37Chr X, 153171370: 153171370
16AVPR2NM_ 000054.4(AVPR2): c.541C> T (p.Arg181Cys)SNVPathogenicrs104894757GRCh37Chr X, 153171501: 153171501
17AVPR2NM_ 000054.4(AVPR2): c.313T> G (p.Phe105Val)SNVPathogenicrs104894758GRCh37Chr X, 153171273: 153171273
18AVPR2NM_ 000054.4(AVPR2): c.137T> A (p.Ile46Lys)SNVPathogenicrs104894759GRCh37Chr X, 153171097: 153171097
19AVPR2NM_ 000054.4(AVPR2): c.310C> T (p.Arg104Cys)SNVPathogenicrs104894760GRCh37Chr X, 153171270: 153171270
20AQP2NM_ 000486.5(AQP2): c.559C> T (p.Arg187Cys)SNVPathogenicrs104894328GRCh37Chr 12, 50348446: 50348446
21AQP2NM_ 000486.5(AQP2): c.439G> A (p.Ala147Thr)SNVPathogenicrs104894334GRCh37Chr 12, 50348016: 50348016
22AVPR2NM_ 000054.4(AVPR2): c.388A> T (p.Ile130Phe)SNVPathogenicrs796052096GRCh37Chr X, 153171348: 153171348
23AVPR2NM_ 000054.4(AVPR2): c.966delC (p.Trp323Glyfs)deletionPathogenicrs886040961GRCh37Chr X, 153172032: 153172032
24AQP2NM_ 000486.5(AQP2): c.763C> T (p.Gln255Ter)SNVPathogenicrs370879515GRCh37Chr 12, 50349338: 50349338
25AQP2NM_ 000486.5(AQP2): c.223T> G (p.Cys75Gly)SNVLikely pathogenicrs193922494GRCh37Chr 12, 50344836: 50344836
26AQP2NM_ 000486.5(AQP2): c.560G> A (p.Arg187His)SNVLikely pathogenicrs193922495GRCh37Chr 12, 50348447: 50348447
27AQP2NM_ 000486.5(AQP2): c.785delC (p.Pro262Argfs)deletionLikely pathogenicrs193922496GRCh37Chr 12, 50349360: 50349360
28AVPR2NM_ 000054.4(AVPR2): c.176T> C (p.Leu59Pro)SNVLikely pathogenicrs193922112GRCh37Chr X, 153171136: 153171136
29AVPR2NM_ 000054.4(AVPR2): c.290T> C (p.Leu97Pro)SNVLikely pathogenicrs193922113GRCh37Chr X, 153171250: 153171250
30AVPR2NM_ 000054.4(AVPR2): c.409C> G (p.Arg137Gly)SNVLikely pathogenicrs104894761GRCh38Chr X, 153905915: 153905915
31AVPR2NM_ 000054.4(AVPR2): c.424delT (p.Cys142Alafs)deletionLikely pathogenicrs193922114GRCh37Chr X, 153171384: 153171384
32AVPR2NM_ 000054.4(AVPR2): c.472delC (p.Arg158Glyfs)deletionLikely pathogenicrs193922115GRCh37Chr X, 153171432: 153171432
33AVPR2NM_ 000054.4(AVPR2): c.554delG (p.Gly185Valfs)deletionLikely pathogenicrs193922116GRCh37Chr X, 153171514: 153171514
34AVPR2NM_ 000054.4(AVPR2): c.673C> T (p.Gln225Ter)SNVLikely pathogenicrs193922117GRCh37Chr X, 153171633: 153171633
35AVPR2NM_ 000054.4(AVPR2): c.752_ 758delGCCGGAC (p.Arg251Glnfs)deletionLikely pathogenicrs193922118GRCh37Chr X, 153171712: 153171718
36AVPR2NM_ 000054.4(AVPR2): c.770delG (p.Gly257Valfs)deletionLikely pathogenicrs193922119GRCh37Chr X, 153171730: 153171730
37AVPR2NM_ 000054.4(AVPR2): c.819_ 821delGCT (p.Leu274del)deletionLikely pathogenicrs193922120GRCh37Chr X, 153171779: 153171781
38AVPR2NM_ 000054.4(AVPR2): c.838dupT (p.Tyr280Leufs)duplicationPathogenicrs193922121GRCh37Chr X, 153171798: 153171798
39AVPR2NM_ 000054.4(AVPR2): c.853G> C (p.Ala285Pro)SNVLikely pathogenicrs193922122GRCh37Chr X, 153171813: 153171813
40AVPR2NM_ 000054.4(AVPR2): c.963C> A (p.Asn321Lys)SNVLikely pathogenicrs193922123GRCh37Chr X, 153172029: 153172029
41AVPR2NM_ 000054.4(AVPR2): c.335G> T (p.Cys112Phe)SNVLikely pathogenicrs1057518723GRCh37Chr X, 153171295: 153171295
42AVPR2NM_ 000054.4(AVPR2): c.878G> A (p.Trp293Ter)SNVPathogenicGRCh37Chr X, 153171838: 153171838

Expression for genes affiliated with Diabetes Insipidus, Nephrogenic

About this section
Search GEO for disease gene expression data for Diabetes Insipidus, Nephrogenic.

Pathways for genes affiliated with Diabetes Insipidus, Nephrogenic

About this section

Pathways related to Diabetes Insipidus, Nephrogenic according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.3CLCNKA, SLC12A1
28.6AQP2, AQP3, AQP4, AVP, AVPR2
3
Show member pathways
7.5AQP1, AQP2, AQP3, AQP4, AQP7, AVP
4
Show member pathways
5.8AQP1, AQP2, AQP3, AQP4, AQP7, ATP6V0A4

GO Terms for genes affiliated with Diabetes Insipidus, Nephrogenic

About this section

Cellular components related to Diabetes Insipidus, Nephrogenic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1basolateral plasma membraneGO:00163239.7AQP1, AQP2, AQP3, AQP4
2apical plasma membraneGO:00163249.6AQP1, AQP2, ATP6V0A4, MIP, SLC12A1
3integral component of plasma membraneGO:00058877.8AQP1, AQP2, AQP4, AQP7, AVPR2, CLCNKA
4integral component of membraneGO:00160216.1AQP1, AQP2, AQP3, AQP4, AQP7, ATP6V0A4
5membraneGO:00160206.1AQP1, AQP2, AQP3, AQP4, AQP7, ATP6V0A4
6plasma membraneGO:00058865.3AQP1, AQP2, AQP3, AQP4, AQP7, ATP6V0A4

Biological processes related to Diabetes Insipidus, Nephrogenic according to GeneCards Suite gene sharing:

(show all 15)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of systemic arterial blood pressureGO:000308410.7AVP, AVPR2
2positive regulation of vasoconstrictionGO:004590710.7AVP, AVPR2
3cellular response to copper ionGO:007128010.7AQP1, AQP2
4cellular response to mercury ionGO:007128810.7AQP1, AQP2
5renal water transportGO:000309710.6AQP1, AQP2
6hyperosmotic salinity responseGO:004253810.6AQP1, AVP
7odontogenesisGO:004247610.5AQP1, AQP3
8renal water absorptionGO:007029510.5AQP1, AQP3
9multicellular organismal water homeostasisGO:005089110.0AQP1, AQP4, AVP
10glycerol transportGO:00157939.7AQP1, AQP2, AQP3, AQP7
11renal water homeostasisGO:00030919.1AQP1, AQP2, AQP3, AQP4, AVP, AVPR2
12excretionGO:00075888.5AQP2, AQP3, AQP7, ATP6V0A4, AVPR2, CLCNKA
13ion transmembrane transportGO:00342208.4AQP2, AQP4, ATP6V0A4, CLCNKA, MIP, SLC12A1
14water transportGO:00068337.8AQP1, AQP2, AQP3, AQP4, AQP7, AVP
15transportGO:00068106.7AQP1, AQP2, AQP3, AQP4, AQP7, ATP6V0A4

Molecular functions related to Diabetes Insipidus, Nephrogenic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1glycerol transmembrane transporter activityGO:001516810.5AQP1, AQP2
2glycerol channel activityGO:001525410.1AQP3, AQP7
3water transmembrane transporter activityGO:00053729.3AQP1, AQP2, AQP4
4transporter activityGO:00052158.9AQP1, AQP2, AQP3, AQP4, MIP
5water channel activityGO:00152508.2AQP1, AQP2, AQP3, AQP4, AQP7, MIP

Sources for Diabetes Insipidus, Nephrogenic

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet